Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation

被引：10

作者：

Miyauchi, Shunsaku ^{[1
]}

Shien, Kazuhiko ^{[1
]}

Takeda, Tatsuaki ^{[2
]}

Araki, Kota ^{[1
]}

Nakata, Kentaro ^{[1
]}

Miura, Akihiro ^{[1
]}

Takahashi, Yuta ^{[1
]}

Kurihara, Eisuke ^{[1
]}

Ogoshi, Yusuke ^{[1
]}

Namba, Kei ^{[1
]}

Suzawa, Ken ^{[1
]}

Yamamoto, Hiromasa ^{[1
]}

Okazaki, Mikio ^{[1
]}

Soh, Junichi ^{[1
]}

Tomida, Shuta ^{[4
]}

Yamane, Masaomi ^{[1
]}

Sakaguchi, Masakiyo ^{[3
]}

Toyooka, Shinichi ^{[1
]}

机构：

[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Breast & Endocrinol Surg, Okayama, Japan

[2] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Pharm, Okayama, Japan

[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cell Biol, Okayama, Japan

[4] Okayama Univ Hosp, Ctr Comprehens Genom Med, Okayama, Japan

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 05期

关键词：

Pan-RAF inhibitor; LY3009120; non-small cell lung cancer; BRAF mutation; DABRAFENIB PLUS TRAMETINIB; PRECLINICAL MODELS; OPEN-LABEL; FEATURES; RESISTANCE;

D O I：

10.21873/anticanres.14237

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The therapeutic strategy for patients with non-small-cell lung cancer (NSCLC) harboring the BRAF non-V600E mutation has not been established. LY3009120, a newly discovered pan-RAF inhibitor, has shown strong antitumor effects in cancers with various BRAF genotypes. This study investigated the antitumor effects of LY3009120 in NSCLC cells harboring the BRAF non-V600E mutation. Materials and Methods: We examined the antitumor effects of LY3009120 by MTS assay and flow cytometry. We analyzed the expression status of proteins by western blot. The mouse xenograft models were used for the in vivo experiments. Results: LY3009120 suppressed BRAF-related downstream pathway molecules and induced cleavage of poly ADP-ribose polymerase in all examined NSCLC cell lines. LY3009120 also inhibited in vivo tumor growth in NSCLC cells harboring the BRAF non-V600E mutation. Conclusion: LY3009120 is a potent therapeutic agent for patients with BRAF non-V600E mutant NSCLC.

引用

页码：2667 / 2673

页数：7

共 50 条

[41] AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes
Wang, Hongbin
Quan, Haitian
Lou, Liguang
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 489 (01) : 14 - 20
[42] Design and rationale of a first in human (FIH) phase 1/1b study evaluating KIN-2787, a potent and highly selective pan-RAF inhibitor, in adult patients with BRAF- and NRAS-mutation positive solid tumors.
McKean, Meredith
Perez, Cesar A.
Kato, Shumei
Spira, Alexander I.
Xing, Yan
Xie, Hao
Millward, Michael
Olszanski, Anthony
Kobayashi, Ken
Miller, Nichol
Severson, Paul
Tam, Betty
Unger, Caro
CANCER RESEARCH, 2022, 82 (12)
[43] Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer
Kawada, Ichiro
Hasina, Rifat
Arif, Qudsia
Mueller, Jeffrey
Smithberger, Erin
Husain, Aliya N.
Vokes, Everett E.
Salgia, Ravi
CANCER RESEARCH, 2014, 74 (03) : 884 - 895
[44] Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells
Plangger, Adelina
Rath, Barbara
Hochmair, Maximilian
Funovics, Martin
Hamilton, Gerhard
TRANSLATIONAL ONCOLOGY, 2021, 14 (12):
[45] OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations
Riveiro, Maria E.
Astorgues-Xerri, Lucile
Vazquez, Ramiro
Frapolli, Roberta
Kwee, Ivo
Rinaldi, Andrea
Odore, Elodie
Rezai, Keyvan
Bekradda, Mohamed
Inghirami, Giorgio
D'Incalci, Maurizio
Noel, Kay
Cvitkovic, Esteban
Raymond, Eric
Bertoni, Francesco
ONCOTARGET, 2016, 7 (51) : 84675 - 84687
[46] A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature
Zhu, Qi
Jiang, Mingyun
Li, Wenfei
Sun, Shuangli
Li, Jisheng
Stebbing, Justin
Liang, Xiaodong
Peng, Ling
FRONTIERS IN ONCOLOGY, 2022, 12
[47] Pifithrin-μ, an Inhibitor of Heat-Shock Protein 70, Can Increase the Antitumor Effects of Hyperthermia Against Human Prostate Cancer Cells
Sekihara, Kazumasa
Harashima, Nanae
Tongu, Miki
Tamaki, Yukihisa
Uchida, Nobue
Inomata, Taisuke
Harada, Mamoru
PLOS ONE, 2013, 8 (11):
[48] Antitumor Effects of a Sirtuin Inhibitor, Tenovin-6, against Gastric Cancer Cells via Death Receptor 5 Up-Regulation
Hirai, Sachiko
Endo, Shinji
Saito, Rie
Hirose, Mitsuaki
Ueno, Takunori
Suzuki, Hideo
Yamato, Kenji
Abei, Masato
Hyodo, Ichinosuke
PLOS ONE, 2014, 9 (07):
[49] Targeting non-small cell lung cancer cells harboring a PIK3CA mutation by a novel and oral PI3K selective inhibitor, PF-4989216
Walls, Marlena
Mehta, Pramod P.
Baxi, Sangita M.
Liu, Kevin
Li, Chunze
Smeal, Tod
Yin, Min-Jean
CANCER RESEARCH, 2011, 71
[50] Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation
Fang, Douglas D.
Zhang, Cathy C.
Gu, Yin
Jani, Jitesh P.
Cao, Joan
Tsaparikos, Konstantinos
Yuan, Jing
Thiel, Melissa
Jackson-Fisher, Amy
Zong, Qing
Lappin, Patrick B.
Hayashi, Tomoko
Schwab, Richard B.
Wong, Anthony
John-Baptiste, Annette
Bagrodia, Shubha
Los, Geritt
Bender, Steve
Christensen, James
VanArsdale, Todd
PLOS ONE, 2013, 8 (06):

← 1 2 3 4 5 →